Sep 08, 2022 / 01:00PM GMT
Stephane Bancel - Moderna, Inc. - CEO & Director
Well, good morning, everybody, or good afternoon or good evening for those of you joining online. Welcome back to Moderna R&D Day. Some of you have been with us for 6 years now. The first one was September 2017 in New York City. And welcome to those of you that are coming to this first time to Moderna R&D Day.
The team and I are very excited to share with you a lot of new clinical data, a lot of news on some of our key Phase III programs today in the respiratory space. So, of course, we'll be making forward-looking statements. Investing in Moderna entails risk. You can find all the risk factors on our website or the SEC website.
As you know, since the first day when we started Moderna, the period has really excited us about the potential of using mRNA as a new drug modality was the software like nature of mRNA. mRNA, as you all know by now, is an information molecule. And that's the piece that's really got us very excited about what we could do for patients using this new technology, if we could find a way to make it work. And
Moderna Inc R&D Day Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers